Compare ZDGE & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | IGC |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.2M | 32.0M |
| IPO Year | 2016 | 2005 |
| Metric | ZDGE | IGC |
|---|---|---|
| Price | $2.27 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 74.3K | ★ 477.8K |
| Earning Date | 10-26-2026 | 11-17-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ 94.12 | 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,626,000.00 | $1,271,000.00 |
| Revenue This Year | $1.15 | N/A |
| Revenue Next Year | $6.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.58 | N/A |
| 52 Week Low | $2.13 | $0.08 |
| 52 Week High | $4.70 | $0.40 |
| Indicator | ZDGE | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 29.04 | 32.29 |
| Support Level | N/A | $0.08 |
| Resistance Level | $3.19 | $0.30 |
| Average True Range (ATR) | 0.18 | 0.02 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 23.36 | 66.50 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.